News | May 03, 2025
Zydus Lifesciences completes 25 years of listing on NSE
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
The Q1 2025 also witnessed a successful launch of Allegra D
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
This approval authorizes the company to export Ibuprofen to the Chinese markets
Investment demonstrates confidence in America’s commitment to science and innovation
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Subscribe To Our Newsletter & Stay Updated
